Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Keeps Neutral Rating at HC Wainwright

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “neutral” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports.

EYPT has been the topic of a number of other research reports. Jefferies Financial Group lowered Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price target on the stock. in a research report on Monday. Citigroup lowered their price objective on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a research report on Tuesday, August 18th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $5.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, August 18th. Guggenheim cut Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday. Finally, Chardan Capital cut Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 target price on the stock. in a report on Tuesday, August 18th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.25.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ:EYPT opened at $0.44 on Tuesday. Eyepoint Pharmaceuticals has a 52 week low of $0.40 and a 52 week high of $19.11. The firm has a market cap of $37.93 million, a PE ratio of -0.12 and a beta of 1.67. The firm’s fifty day moving average is $4.77 and its 200-day moving average is $10.30.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The company had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. Sell-side analysts forecast that Eyepoint Pharmaceuticals will post -3.51 EPS for the current year.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors have recently bought and sold shares of EYPT. KBC Group NV bought a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter worth about $29,000. Integrated Wealth Concepts LLC bought a new stake in shares of Eyepoint Pharmaceuticals during the 2nd quarter valued at about $72,000. Cyndeo Wealth Partners LLC grew its stake in Eyepoint Pharmaceuticals by 46.8% during the third quarter. Cyndeo Wealth Partners LLC now owns 35,519 shares of the company’s stock worth $116,000 after purchasing an additional 11,329 shares during the period. Pictet Asset Management Holding SA acquired a new stake in Eyepoint Pharmaceuticals during the first quarter worth approximately $141,000. Finally, Engineers Gate Manager LP bought a new stake in Eyepoint Pharmaceuticals in the second quarter worth approximately $161,000. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals News Summary

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint plans to reduce operating expenses and concentrate resources on its late-stage DURAVYU program for DME. The narrower focus could extend the company’s cash runway and preserve value in its remaining lead program. EyePoint Announces Strategic Prioritization
• Neutral Sentiment: Unusual options activity included purchases of 7,885 call contracts, approximately 69% above typical daily call volume. This may indicate speculative interest or expectations of a rebound, but it does not change the company’s fundamental outlook.
• Negative Sentiment: EyePoint reported disappointing topline results from the LUCIA Phase 3 trial of DURAVYU in wet AMD. The setback led the company to halt related clinical trials early, removing a major potential catalyst and raising doubts about the drug’s commercial prospects in the market. EyePoint Announces Topline Results from LUCIA
• Negative Sentiment: The company announced a 53% workforce reduction as part of its restructuring after the clinical-trial setback. Although the cuts should lower expenses, they also signal a substantially reduced operating plan and weaker near-term growth prospects. EyePoint Pharmaceuticals to Cut 53% of Workforce
• Negative Sentiment: Guggenheim downgraded EYPT from “buy” to “neutral,” while Jefferies moved from “buy” to “hold.” Jefferies assigned a $1.00 price target, implying substantial upside from the current level, but the downgrade reflects sharply reduced confidence following the LUCIA results.
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations on behalf of shareholders who suffered losses. The inquiry adds legal and reputational risk, although it does not establish wrongdoing. EyePoint Pharmaceuticals Investigation Notice

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.